(Date:5/15/2008)... - Unprecedented amount of research reflects depth... worldwide to develop new treatments for ...session to highlight impact of Zometa(R), the lead...s with early-stage breast cancer, - Four oral ses...tinuous, inhibitor of mTOR, including first result...
(Date:5/15/2008)...cellent results obtained with a newly cleared devi...laques of interest that are associated with ...URLINGTON, Mass., May 15 /- InfraReDx... Hospital in Royal Oak, Mich., have,successfully u...patient,undergoing a cardiac catheterization. This...
(Date:5/15/2008)...ONITA SPRINGS, Fla., May 15 /- Tigris...on of a Cooperative Research and,Development Agree...CI) to,collaborate on clinical and preclinical dev...Phase I development. AFP-464 is converted to,metab...p53 activation and,apoptosis., This is part of a ...
(Date:5/15/2008)... Line Data Expected soon after CEA Trial data repo... -, SAN FRANCISCO, May 15 /PRNewswire-FirstCa... a biotechnology company focused on the developmen... disease, announced today that,it has completed pa...CS),study. The ACS study is one of three Phase 2 t...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Researchers Spot Link Between Heart Disease Income 6647 1Researchers Spot Link Between Heart Disease Income 6647 2Use of intraoperative MRI adds time but care changing information to neurosurgery study shows 6643 1Lupus Research Institute strategy delivers 2430 million in national funding 1271 1Lupus Research Institute strategy delivers 2430 million in national funding 1271 2Bill Booker Receives American Diabetes Associations Distinguished Service Award 6639 1Bill Booker Receives American Diabetes Associations Distinguished Service Award 6639 2Bill Booker Receives American Diabetes Associations Distinguished Service Award 6639 3...Future Trials, Other,Programs --, GAITHERSBURG, Md...-FirstCall/ -- Iomai Corporation today announced r...ial of its patch-based,vaccine for travelers, diar...y of a range of vaccine doses to generate an immun...bacteria -- the,most common cause of travelers, di...
...6, 2007 - Columbia,Laboratories, Inc. (NASDAQ: CBR...he ongoing data analysis of the recently-completed...e III clinical,trial of PROCHIEVE(R) 8% (progester...men with a previous preterm birth earlier than,35 ...PROCHIEVE 8%,in delaying cervical shortening. A sh...
Other Medicine Technology:Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 2Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 3Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 4Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3(Date:5/16/2008)...Newswire/ -- Less than a week after,committing med...stated by,Cyclone Nargis, Project HOPE, an interna...e organization, is again mobilizing its full,resou...or the people of,central China devastated by the m...ives., "I am saddened by the vast loss of life an...
(Date:5/16/2008)...people who didn,t have cancer as children, study f... -- Adults who had cancer as children or teens are... a new study found. , And the heart problems s...d not suffer cancer as children. , Childhood ca...mes increased risk of having heart disease compare...
(Date:5/16/2008)...t The University of Texas M. D. Anderson Cancer Ce... leukemia cells by shutting down their energy sour...ical study, Lauren Akers, D.O., postdoctoral fello...erson, found that combining a novel glycolysis inh...duced more than 90 percent cell death in human tis...
(Date:5/16/2008)...hs School of Nursing and Midwifery, has won the In...an Nursing Awards. , Professor Rickard won top ... during testing procedures, reducing the risk of a...lready ill patients. The award was announced last ...inment complex. , Nurses routinely take blood s...
Breaking Medicine News(10 mins):Health News:Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 3Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Research talent wins national Innovation in Nursing award 2...truction caused by the Indian Ocean tsunami, the K...hquake in late 2005. The tsunami was responsible f...n 100,000 still missing.// When the early images o... were tsunami’s hot favorites. Upon intent observa...
...currently in the experimental phase has offered ho... latent infections as well. The mechanism of actio...for conventional treatment. The drug targets slow... disease process and induces selective killing of ...
...have now developed a new tool to determine if heig...ging. The test is as simple as asking the patient ... the present height. // This would provide a rough...alculation approximates to 6cm (difference between...
...splant could be determined in just one week by mea...actor (TNF). // The inflammatory marker can help d...vs. host disease (GVHD), the most commonly observe... The early identification of related complication ...
Other Medicine News:Health News:New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment 2Health News:TNF Protein Can Predict GVHD Bone Marrow Transplant Recipients 2The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures.
The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue.
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor.
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains.
Medicine Products: